Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer
/in Hyperthermia, International Publications, Ovarian CancerDendritic cell-based vaccines in breast and gynaecologic cancer
/in Breast Cancer, Cervical Cancer, Dendritic Cells, International Publications, Ovarian CancerTRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients
/in International Publications, Ovarian CancerDendritic cells in vaccination therapies of malignant diseases
/in International Publications, Ovarian CancerNovel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer
/in International Publications, Ovarian CancerNovel target antigens for dendritic cell-based immunotherapy against ovarian cancer
/in International Publications, Ovarian CancerVaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial
/in Dendritic Cells, Endometrial Cancer, International Publications, Ovarian CancerInduction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
/in Dendritic Cells, Endometrial Cancer, International Publications, Ovarian Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer